Abstract 901P
Background
Chemoradiation (CRT) in patients (pts) with locally advanced head and neck squamous cell cancer (HNSCC) is associated with significant toxicities, including oral mucositis (OM). The gut microbiome (GM) is an emerging biomarker of treatment outcomes and adverse events. This study aimed to investigate the role of GM composition to predict CRT toxicities in HNSCC pts, including development of severe OM.
Methods
We prospectively collected fecal samples of 52 pts with HNSCC undergoing CRT. Using shotgun metagenomic sequencing and MetaPhlAn4 pipeline, LefSe differences in GM composition at baseline were assessed according to CTCAE v4.0 toxicity grading including OM and enteral feeding tube requirement. Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan-Meier method.
Results
Most tumors (n=40) were p16-positive, including oropharyngeal (n=35) and unknown primaries (n=4). TNM staging was III-IV in 54% (n=28). After a median follow-up of 27 mo, the 12-mo OS and PFS were 96% and 84%, respectively. In terms of toxicity, OM was seen in all pts, and 22 pts (42%) developed grade ≥3 OM. Thirteen pts (25%) required enteral feeding. Grade ≥3 OM was associated with a significant decrease in OS (p=0.02) even when accounting for staging and p16 status in multivariate analysis (MVA; p<0.05), as well as a numerically shorter PFS (p=0.09). No baseline characteristic correlated with increased risk of severe OM in MVA. However, GM beta-diversity differed between grade 1-2 and grade 3 OM (PERMANOVA p=0.04) but there was no difference in alpha-diversity. Pts with severe OM had distinct GM enriched with Mediterraneibacter (Ruminococcus gnavus) and members of the Clostridiaceae family, including Hungatella hathewayi. In pts with mild OM, Eubacterium rectale, Alistipes putredinis and members of the Ruminococcaceae family were overrepresented. We observed similar microbiome differences in pts requiring enteral feeding.
Conclusions
Severe OM was associated with decreased OS and PFS in pts with HNSCC undergoing CRT. Pts who developed severe OM or required enteral feeding had a distinct GM enriched with deleterious bacteria that have been associated with resistance to immune checkpoint inhibitors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Oncobiome grant #825410.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
818TiP - REFRaME-O1/ENGOT-OV79/GOG-3086: A phase II/III open-label study evaluating the efficacy and safety of luveltamab tazevibulin versus investigator’s choice of chemotherapy in women with relapsed platinum-resistant epithelial ovarian cancer expressing folate receptor alpha (FolRα)
Presenter: R. Wendel Naumann
Session: Poster session 12
819TiP - FONTANA: A phase I/IIa study of AZD5335 as monotherapy and in combination with anti-cancer agents in patients with solid tumours
Presenter: Funda Meric-Bernstam
Session: Poster session 12
820TiP - A randomized phase II study of secondary cytoreductive surgery (CRS) in patients with relapsed ovarian cancer who have progressed on PARP inhibitor maintenance (KGOG 3067/SOCCER-P trial)
Presenter: Hyun-woong Cho
Session: Poster session 12
821TiP - Phase I study of ceralasertib (cerala) in combination with AZD5305 in patients (pts) with advanced/metastatic ovarian cancer (OC) previously treated with PARP inhibitors (PARPis)
Presenter: Geoffrey Shapiro
Session: Poster session 12
862P - Clinical utility of circulating tumor HPV16 DNA detection in plasma from oropharyngeal squamous cell carcinoma patients
Presenter: Ana Carolina de Carvalho
Session: Poster session 12
863P - Microbiota and cytokines profile in patients (pts) affected by recurrent metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with immune checkpoint inhibitors (ICIs) +/- chemotherapy (CT) and prebiotic inulin in the PRINCESS study
Presenter: Danilo Galizia
Session: Poster session 12
864P - Serial cell-free tumor DNA in prognosing survival in patients with head and neck squamous cell carcinoma treated with upfront surgery
Presenter: Grégoire Marret
Session: Poster session 12
865P - Molecular analysis of surgical margins in early oral carcinomas (OSCC)
Presenter: Antoine Moya-Plana
Session: Poster session 12
866P - Prognostic performance of a genome-wide methylome enrichment platform in head and neck cancer
Presenter: Geoffrey Liu
Session: Poster session 12
867P - Predicting HPV-association using regular H&E slides can identify subgroups of patients with favorable prognosis at a highly detailed level
Presenter: Jens Peter Klussmann
Session: Poster session 12